|
|
| Product Name: | GP2 | | Synonyms: | IISAVVGIL;ILE-ILE-SER-ALA-VAL-VAL-GLY-ILE-LEU;H-ILE-ILE-SER-ALA-VAL-VAL-GLY-ILE-LEU-OH;HER-2/NEU (654-662);HER2/NEU (654-662) GP2;GP2;L-Leucine, L-isoleucyl-L-isoleucyl-L-seryl-L-alanyl-L-valyl-L-valylglycyl-L-isoleucyl-;HER2/nue 654-662 | | CAS: | 160790-21-6 | | MF: | C42H77N9O11 | | MW: | 884.11 | | EINECS: | | | Product Categories: | Peptide | | Mol File: | Mol File |  |
| Boiling point | 1209.5±65.0 °C(Predicted) | | density | 1.147±0.06 g/cm3(Predicted) | | pka | 3.41±0.10(Predicted) | | form | Solid | | color | White to off-white | | Sequence | Ile-Ile-Ser-Ala-Val-Val-Gly-Ile-Leu |
| Uses | HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers[1][2]. | | References | [1] Sun Y, et al. Observing the temperature dependent transition of the GP2 peptide using terahertz spectroscopy. PLoS One. 2012;7(11):e50306. DOI:10.1371/journal.pone.0050306
[2] Tanaka Y, et al. Modification of the HER2/NEU-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytes. Int J Cancer. 2001 Nov;94(4):540-4. DOI:10.1002/ijc.1508 |
| | GP2 Preparation Products And Raw materials |
|